2 active not recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 2 |
Follow Scleroderma, Diffuse: new trials by email Literature Review of Scleroderma, Diffuse trials Research Report on Scleroderma, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) Anifrolumab (blinded), Placebo (blinded), Anifrolumab (unblinded, open label) - Systemic Sclerosis, Scleroderma | Phase 3 | Active not recruiting | AstraZeneca | 314 | 2023-11-08 | 2026-09-30 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis BMS-986278, BMS-986278 Placebo - Progressive Pulmonary Fibrosis | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 1057 | 2023-10-25 | 2026-04-23 |
Lung Diseases, Interstitial (2) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Connective Tissue Diseases (1) · Fibrosis (1) · Immune System Diseases (1) · Pulmonary Fibrosis (1) · Sarcoidosis (1) · Scleroderma, Systemic (1)
Lung Diseases (2) · Respiratory Tract Diseases (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Arthritis (1) · Autoimmune Diseases (1) · Connective Tissue Diseases (1) · Hemic and Lymphatic Diseases (1) · Hypersensitivity (1) · Hypersensitivity, Delayed (1) · Immune System Diseases (1) · Joint Diseases (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Musculoskeletal Diseases (1)
anifrolumab (1)
AstraZeneca (1) · Bristol-Myers Squibb (1)
Austria (2) · Belgium (2) · Canada (2) · China (2) · France (2) · Germany (2) · Hungary (2) · India (2) · Israel (2) · Italy (2) · Japan (2) · Malaysia (2) · Mexico (2) · Netherlands (2) · Poland (2)
2023 (2)